EGFR and non-small cell lung carcinoma: In the subgroup of 2,913 presumably EGFR mutation-negative patients with progressing non-small cell lung cancer who did not receive EGFR-TKI therapy, 46.3% (1,348/2,913) were alive at the end of year 3.